Oncología Hepática
Klinikum der Universität München
Múnich, AlemaniaPublications in collaboration with researchers from Klinikum der Universität München (28)
2024
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Journal of Clinical Oncology, Vol. 42, Núm. 23, pp. 2790-2799
-
Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
JHEP Reports, Vol. 6, Núm. 4
-
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial
United European Gastroenterology Journal
2023
-
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)
Frontiers in Pharmacology
-
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
JHEP Reports, Vol. 5, Núm. 5
-
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
European Radiology, Vol. 33, Núm. 1, pp. 493-500
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516
-
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients
Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309
-
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Frontiers in Pharmacology, Vol. 14
2022
-
A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy
Digestive Diseases, Vol. 40, Núm. 3, pp. 322-334
-
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726
-
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485
-
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
European Radiology, Vol. 32, Núm. 2, pp. 1320-1329
-
Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial
Frontiers in Gastroenterology, Vol. 1
-
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
Cancer Imaging, Vol. 22, Núm. 1
-
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria
Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901
-
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
Biomedicines, Vol. 10, Núm. 5
-
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 9, pp. 2487-2496
-
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma
British Journal of Cancer, Vol. 126, Núm. 2, pp. 211-218